KEY TAKEAWAYS
- The study aimed to investigate the effectiveness of Std KELIM and PtRR Score in predicting platinum sensitivity in patients with advanced EOC.
- Researchers noted that Std KELIM provides early chemosensitivity insights, aiding management alongside surgical status.
Neoadjuvant chemotherapy followed by interval debulking surgery is currently a common treatment option for advanced epithelial ovarian cancer (EOC). The Standardized CA-125 ELIMination rate constant K (Std KELIM) and the Platinum Resistant Recurrence (PtRR) Score have been proposed as markers of tumor chemosensitivity.
Nina Oufkir and the team aimed to validate these tools for predicting platinum sensitivity in a real-world population of patients with advanced EOC treated with neoadjuvant chemotherapy.
They performed an inclusive analysis of all patients with advanced EOC treated with neoadjuvant chemotherapy at the Institut Curie between 2000 and 2015. The Std KELIM was calculated using CA-125 concentrations from the first 100 days of chemotherapy.
The predictive value of Std KELIM and PtRR scores for the risk of subsequent platinum resistance was assessed through receiver operating characteristic (ROC) curve analysis, logistic regression, and calibration curves. Kaplan-Meier survival analysis was conducted to evaluate the treatment-free interval from platinum therapy (TFIp) and overall survival (OS).
About 149 patients had available Std KELIM data. The area under the curve (AUC) for PtRR was 0.67. A low Std KELIM was significantly associated with platinum resistance (OR = 0.19 [95% CI 0.06, 0.53], P = 0.002) based on univariate analysis. The PtRR calibration curve indicated a slight but significant underestimation (P = 0.02) of the probability of platinum resistance.
Favorable Std KELIM (≥ 1), both alone and in combination with the completeness of surgery, was associated with significantly better survival outcomes in terms of TFIp and OS.
The study concluded that Std KELIM serves as an early prognostic marker of chemosensitivity in real-life settings, complementing surgical status. It can help clinicians in the early management of patients by identifying those with a worse prognosis.
No funding information was given.
Source: https://pubmed.ncbi.nlm.nih.gov/39039554/
Oufkir N, Rouzier R, Paoletti X, et al. (2024). “External validation of Standardized KELIM and platinum-resistant recurrence scores in patients with advanced epithelial ovarian cancer.” J Ovarian Res. 2024 Jul 22;17(1):152. doi: 10.1186/s13048-024-01476-3. PMID: 39039554; PMCID: PMC11265035.
